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Abstract
Current hormonal therapies for prostate cancer are effective initially, but inevitably tumours
progress to an advanced, metastatic stage, often referred to as ‘androgen independent’. However,
the androgen receptor (AR) signalling pathway is still key for their growth. It is speculated that
tumours escape hormonal control via reduction in corepressor proteins. Manipulating such
proteins is thus a potential therapeutic strategy to halt or even reverse tumour progression.
We aimed to elucidate the effects of altering levels of the AR corepressor and androgen-target
proteinprohibitin(PHB)onprostatetumourgrowth.Prostatecancercellsincorporatinganintegrated
androgen-responsive reporter gene and stably expressing vectors to inducibly overexpress or
knockdown PHB were generated and used to assess effects on androgen signalling (by real time
imaging) and tumour growth both in culture and in vivo. PHB overexpression inhibited AR activity
and prostate-speciﬁc antigen (PSA) expression as well as androgen-dependent growth of cells,
inducing rapid accumulation in G0/G1. Conversely, reduction in PHB increased AR activity, PSA
expression, androgen-mediated growth and S-phase entry. In vivo, doxycycline-induced PHB
regulation resulted in marked changes in AR activity, and showed signiﬁcant effects upon tumour
growth. Overexpression led to tumour growth arrest and protection from hormonal starvation,
whereas RNAi knockdown resulted in accelerated tumour growth, even in castrated mice. This
study provides proof of principle that i) reduction in PHB promotes both androgen-dependent and
‘androgen-independent’ tumour growth, and ii) altering AR activity via increasing levels or activity
of corepressors is a valid therapeutic strategy for advanced prostate cancer.
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Introduction
Prostate cancer is the most commonly diagnosed
cancer in males, accounting for 25% of new cases in
both the United States and Europe, where it is the
second and third leading cause of male cancer deaths
respectively (Ferlay et al. 2007, Jemal et al. 2008).
The androgen signalling pathway is central in prostate
cancer progression and therapy, as tumours are
initially dependent upon androgens for growth
(Agoulnik & Weigel 2006). The principal circulating
androgen is testosterone, produced by the testis, while
weaker androgens and precursors are also produced
by the adrenal glands (Kokontis & Liao 1999).
Prostate development is driven by the potent
androgen dihydrotestosterone (DHT), produced
within prostate cells by the action of 5a-reductase
enzymes on testosterone. Cellular responses to
androgens are mediated by the androgen receptor
(AR), a ligand-activated transcription factor and
member of the nuclear receptor superfamily
(Gelmann 2002). In the absence of ligand, AR is
cytoplasmic; ligand binding induces an active
conformation and translocation into the nucleus
where it binds speciﬁc androgen response elements
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inﬂuencing rates of gene transactivation. AR then
recruits regulatory protein complexes to the
promoters of these genes (Tsai & O’Malley 1994).
Response elements for the AR and the closely
related glucocorticoid receptor (GR), progesterone
receptor and mineralocorticoid receptor are hexameric
bipartite binding sites, with the consensus sequence
consisting of an inverted repeat of TGTTCT with a
three nucleotide spacer (Beato et al. 1989). The AR can
bind to these canonical elements, but promoter analysis
of androgen-responsive genes revealed additional non-
consensus response elements with apparent AR
speciﬁcity. Two well-studied examples are the rat
dorsal prostate-speciﬁc probasin (PB) promoter and the
prostate trans-epithelial transporter of IgM (secretory
component or SC) promoter (Dodd et al. 1983, Rennie
et al. 1993, Mostov 1994, Claessens et al. 1996,
Verrijdt et al. 1999). Within these, speciﬁc AREs differ
from the classical inverted TGTTCT, having a greater
similarity to a direct repeat of the same sequence, but
with a change of T–G in the ﬁrst base that increases AR
while decreasing GR binding (Claessens et al. 1996,
Schoenmakers et al. 1999, 2000).
Therapies for advanced prostate cancer usually
involve anti-androgens. Although initially successful,
such therapies inevitably fail and patients relapse with
‘androgen-independent tumours’. However, the AR is
still required for tumour growth, and in many cases,
tumours circumvent the requirement for high levels of
androgens by receptor ampliﬁcation, or mutation
resulting in a receptor with broadened ligand
responsiveness (Brinkmann & Trapman 2000,
Gelmann 2002, Isaacs & Isaacs 2004, Agoulnik &
Weigel 2006). The exact mechanisms of anti-androgen
action are poorly understood, but they appear to
promote the recruitment of repressive protein
complexes, or corepressors, to the AR (Wang et al.
2005, Powell et al. 2006). Which corepressors may be
required for in vivo repression of the AR by anti-
androgens is not known, but potentially these will be
candidates involved in disease progression and in
development of ‘androgen-independent’ growth. One
such potential AR corepressor is prohibitin (PHB).
PHB is a highly conserved 32 kDa protein with dual
roles within the cell (McClung et al. 1995, Coates et al.
1997). Within mitochondria, PHB is located in the
inner membrane where it functions as a chaperone/
holdase complex for newly imported proteins
(Nijtmans et al. 2002). However, PHB has been
found in the nucleus of several steroid hormone-
responsive cell lines where its functions are more
complex. PHB is reported to have tumour suppressor,
anti-proliferative and cell cycle regulation activities,
largely accomplished through its repression of E2F
activity. E2F transcription factors regulate genes
involved in differentiation, proliferation and apoptosis;
and, together with the retinoblastoma (pRb) protein,
they regulate the G1/S transition. PHB appears to
repress E2F via recruitment of HDAC1, NCoR and
BRG1/Brm (Choi et al. 2008), thus condensing
chromatin and silencing gene activation. Overexpres-
sion of PHB results in G1/S arrest and the inhibition of
E2F-mediated apoptosis (Fusaro et al.2 0 0 2 ).
We previously showed that PHB represses ligand-
dependent AR activity and also inhibits androgen-
stimulated growth of prostate cancer cells, in vitro
(Gamble et al. 2007). Furthermore, we found PHB
protein levels in prostate cancer cells to be down-
regulated in response to androgens (Gamble et al.
2004), presumably enabling androgen-stimulated cell
cycle entry and growth. More recently, PHB has been
shown to be a corepressor of the oestrogen receptor
(ERa; He et al. 2008), associating with oestrogen-
regulated promoters in the absence of hormone and
dissociating after hormone treatment. Interestingly,
PHB has been implicated in mediating the anti-
proliferative actions of anti-oestrogens, and reduction
in PHB levels reduced the anti-proliferative actions
of such ER antagonists (Wang et al. 2004). These
studies, together with the report that PHB is required
for the recruitment of the BRG1-containing chromatin
remodelling complex to antagonist-bound AR (Dai
et al. 2008), make PHB an excellent candidate AR
corepressor, important in prostate cancer progression
and therapy. We tested this hypothesis by investigating
the effects of manipulating PHB levels in human
prostate cancer cells on AR activity and tumour cell
growth, in culture and in vivo, in response to hormone
treatment.
Materials and methods
Cell culture
All cells were maintained at 37 8C, 5% CO2, in media
containing 2 mM L-glutamine, 100 units/ml penicillin
and 100 mg/ml streptomycin (Sigma). LNCaP/TR2
cells were maintained in RPMI medium (Sigma)
supplemented with 10% tetracycline-free foetal bovine
serum (Clontech) and 12 mg/ml blasticidin (Invi-
trogen), and LNCaP/Luc with the further addition of
G418 (500 mg/ml). Where cells were further stably
transfected with PHB overexpression or knockdown
plasmids, 0.3 mg/ml zeocin (Invitrogen) was added.
COS-1 cells were maintained in DMEM medium
D A Dart et al.: In vivo role of prohibitin in prostate cancer
www.endocrinology-journals.org 1158(Sigma) supplemented with 10% foetal bovine serum
(First Link UK, Ltd, Brierley Hill, UK). Twenty-four
hours before exposure to androgen, medium was
replaced with ‘starvation medium’ consisting of phenol
red-free RPMI or DMEM medium as appropriate
supplemented with 5% charcoal-stripped foetal bovine
serum (First Link UK).
Reporter construction
A 168 bp fragment containing the minimal thymidine
kinase (tk) promoter from the herpes simplex virus was
cloned into the Sac1/Xho1 site of pGL4 (Promega) to
generate p-tk-Luc. DNA oligomers (EuroﬁnsMWG,
Ebersberg, Germany) coding for the SC1.2 ARE
sequence were ligated into the Sac1/Xba1 site of
p-tk-Luc to generate p-tk-Luc-ARE (Fig. 1A). The 3 kb
fragment of the chicken lysozyme 50-matrix attach-
ment region (MAR) was provided by Georges Vassaux
(CRUK, London, UK). Blunted MAR fragments were
ligated into the Sma1 and BamH1 sites (restriction
mapping conﬁrmed directionality) of p-tk-Luc-ARE to
create pARE.MAR.
Generating a tetracycline-inducible system
LNCaP/TR2 cells expressing the Tet repressor were
generated as described (Gamble et al. 2007) and stably
transfected with the following vectors.PHB cDNA was
cloned into pcDNA4/TO (Invitrogen). For siRNA
knock down, a H1 promoter for RNA pol III
(containing two Tet-repressor binding sites) was
cloned into a promoter-less pcDNA3 vector (Invi-
trogen), generating pcDNA/2!TetR plasmid, then 65
mer oligos for hairpin siRNA against PHB, based on
previously validated RNA duplexes (Gamble et al.
2004), were inserted downstream.
Transient transfection
COS-1 cells grown in 24-well plates were
transfected using Fugene 6 (Roche Products Ltd)
with 1 mg androgen-responsive luciferase reporter,
50 ng AR expression vector (pSVAR) and 100 ng
b-galactosidase control vector (PDM-LAC-Z-b-GAL)
per well.
Figure 1 Construction and testing of androgen-responsive reporter vectors. (A) Sequential construction of vectors. (B) COS-1 cells
were transfected with AR expression vector and luciferase construct as indicated, and then treated with 0.001–10 nM MB for 24 h.
Results are meanGS.E.M. of three experiments. (C) LNCaP/Luc cells were treated with androgens (0–100 nM) for 24 h. Luciferase
activity was assayed and normalized by SRB assay. (D) Increase of luciferase and PSA mRNA transcripts in LNCaP/Luc cells after
6 h treatment with MB. (E) ChIP analysis of the PSA gene promoter and the integrated luciferase reporter promoter in LNCaP/Luc
cells after 2 h MB treatment (10 nM). MB, mibolerone; DHT, dihydrotestosterone; Tes, testosterone; A-dione, androstenedione;
DHEA, dehydroepiandrosterone; PSA, prostate-speciﬁc antigen.
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Cells were washed in ice-cold PBS and lysed in reporter
lysis buffer (Promega). Lysate was mixed with luciferin
substrate(Perkin–Elmer,Warrington,Cheshire,UK)and
light emission measured using the Steadylite luciferase
assay kit (Perkin–Elmer) in a Topcount luminometer
(PackardInstrumentCo.,Meriden,CT,USA).Transfec-
tions were normalized to b-galactosidase activity,
measured using the Galacton Tropix chemiluminescent
kit (Applied Biosystems, Warrington, UK).
Generating stably transfected cell lines
LNCaP/TR2 cells were transfected with linearized
pARE.MAR using Fugene 6 (Roche). Cells were
grown for 24 h before G418 (500 mg/ml) selection
commenced. After 2–3 weeks, single colonies were
expanded into cell lines and tested for luciferase
expression by live-cell imaging, western blotting and
semi-quantitative RT-PCR. The cell line was named
LNCaP/Luc.
RNA extraction and RT-PCR
RT-PCR for prostate-speciﬁc antigen (PSA) and L19
control was carried out as described (Gamble et al.
2007). Luciferase was detected using the primer pairs
50-gctcagcaaggaggtaggtg-30 and 50-tcttaccggtgtc-
caagtcc-30 with 22–24 cycles of 94 8C for 30 s, 54 8C
for 30 s and 70 8C for 1 min. TaqMan PCR assays for
each gene target were performed in triplicate on cDNA
samples in 96-well optical plates on an ABI Prism 7700
Sequence Detection system (PE Applied Biosystems).
For each 20 ml TaqMan reaction, 2 ml cDNA was mixed
with 7 ml PCR-grade water, 10 ml2 !TaqMan Uni-
versal PCR Master Mix (PE Applied Biosystems) and
1 ml Taqman assay probe. PCR parameters were 50 8C
for 2 min, 95 8C for 10 min, 40 cycles of 95 8C for 15 s
and60 8Cfor1 min.DatawererecordedusingSequence
Detector Software (SDS version 2.3; PE Applied
Biosystems). From each ampliﬁcation plot, a threshold
cycle (Ct) value was calculated, representing the PCR
cycle number at which the ﬂuorescence was detectable,
based on the variability of base line data in the ﬁrst 15
cycles. PSA levels were normalized to glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH)levels.
Immunoblotting
Cell pellets were lysed in RIPA buffer. 20 mg of extract
was separated by SDS-PAGE and electroblotted onto
nitrocellulose membranes. Non-speciﬁc binding was
blocked in tris-buffered saline (TBS) with 0.05%
Tween-20 and 5% w/v non-fat dried milk. Primary
antibodies were mouse monoclonals against b-actin
(Abcam, Cambridge, MA, USA @1:5000) or PHB
(Thermo Fisher Scientiﬁc, Cheshire, UK @1:1000).
Peroxidase-labelled rabbit anti-mouse secondary
antibodies (Dako, Ely, UK) were used at 1:2000. The
membrane was then incubated in chemiluminescent
substrate (Amersham), and light emission detected by
autoradiography.
Chromatin immunoprecipitation
Cells (1!10
7) were grown in starvation medium for
3 days, and then treated with hormone (10 nM
mibolerone (MB)) for 2 h. ChIP was performed on
formaldehyde cross-linked cell samples essentially
as described (Zhang et al. 2003). Primer sets for the
PCR included PSA ARE (50-tctgcctttgtcccctagat-30
and 50-aaccttcattccccaggact-30)a n dSC1.2 ARE
(50-gccaagcttacttagatctcgagatctgcggcacgc-30 and
50-ggagagctccggctctttcagttctgcggccgctct-30), both
amplifying a 200 bp fragment across the ARE. 5 ml
of DNA was used for the PCR with 30–35 cycles of
94 8C for 30 s, 57 8C for 45 s and 70 8C for 45 s.
Cell cycle analysis
Cells were grown in starvation medium for
48–72 hGdoxycycline, and then treated with hormone
for 24–48 h. Cells were then trypsinized, washed twice
in PBS, ﬁxed in 70% ethanol at 4 8C, were stained with
5 mg/ml propidium iodide and RNA removed using
50 mg/ml RNase A. FACS analysis was carried out
using a FACS Calibur (Beckton-Dickinson, Oxford,
UK), using linear scale representation of forward and
side scatter during ﬂow analysis, as well as DNA
content. Single cells were gated and the cell cycle
proﬁles measured. A total of 10 000 events were
measured per sample.
Growth of xenografts
Surgically castrated 8-week male BALB/c strain nude
mice (Harlan, Bicester, UK) were injected subcu-
taneously with 0.5 ml LNCaP/Luc cells suspended in
Matrigel (1!10
6 cells/ml). Daily injections of testoster-
one propionate (50 mg in 90% propylene glycol and
10% ethanol) were given until tumours were conﬁrmed
(w2 weeks after challenge). For PHB manipulation
within the LNCaP/Luc cells, doxycycline was adminis-
tered in drinking water (20–200 mg/ml). Tumours were
measured daily using callipers and volumes calculated
using the formula width
2!length/2 (Janik et al.1 9 7 5 ).
Tumourswereallowedtogrowto15 mmdiameter,when
the animals were killed, tumours resected and ﬁxed in
neutral-buffered formalin. Statistical signiﬁcance was
calculated using the Mann–Whitney U analysis.
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were monitored for ill effects. All work was carried out
in accordance with the provisions of the Animals
(Scientiﬁc Procedures) Act 1986 of the United King-
dom (HMSO, London, UK, 1990) and with appropriate
local ethical and Health and Safety approval.
Luciferase imaging
Cells were grown in 24-well plates, and D-luciferin
substrate (Xenogen, 20 ml per well) was added into the
medium. Mice were injected i.p. with D-luciferin
(Caliper Life Sciences Ltd, Runcorn, UK) at
150 mg/kg, 10 min before imaging. Anaesthetized
mice (3% isoﬂurane, Abbott Animal Health UK)
were placed into a light-tight camera box. Light
emission from luciferase was detected by the IVIS
Imaging System 100 series (Xenogen Corporation),
and overlaid as a pseudocolour image with reference
scale, upon a greyscale optical image. Photon emission
was later normalized either to cell number, measured
using the sulphorhodamine B assay as previously
described (Skehan et al. 1990), or to tumour volume.
Measurement of serum doxycycline and
testosterone
Serum was collected from mice given doxycycline
(0–2 mg/ml) in their drinking water for 24 h.
The pcDNA6/TR plasmid (Invitrogen) expressing the
Tet repressor and pcDNA4/TO/Luc (expressing tetra-
cycline-regulated luciferase cDNA) were transiently
transfected (100 ng/well each) into COS-1 cells, grown
on 96-well plates in tetracycline-free medium. This
was replaced by medium containing increasing
doxycycline (0–100 mM) to generate a standard
curve, against which the mouse serum samples were
analysed. Total testosterone from mouse serum was
measured using ELISA kits (Calbiotech, CA, USA).
Histology and immunohistochemistry
Standard protocols were carried out as described
(Powell et al. 2004, 2006). Antibodies used were:
mouse anti-human PHB primary antibody (AbCam Ltd
@1:500); Ki67 (DAKO M7249 @1:50); phospho-
histone H3 (Millipore UK Ltd, Watford, UK 06-570
@1:250). The Vectastain avidin–biotin complex (ABC
from Vector Labs, Peterborough, UK) was used for
detection, using diaminobenzidine chromogenic sub-
strate.Negativecontrolslackingprimaryantibodywere
also carried out. Digital images were captured using
E1000 microscope (Nikon, Kingston upon Thames,
UK) and Eclipse Net image analysis software. Ki67
and phospho-histone H3-positive cell were counted
withinﬁvedifferentareaswithinthetumour,containing
w200 cells each, for four to ﬁve tumours per group.
Results
Generation and characterization of
androgen-responsive reporter cell lines
Our aim was to create a luciferase reporter construct
responding speciﬁcally to androgen stimulation, with
minimal crosstalk with other steroids. This was tested
initially by cotransfection with AR expression vector
into COS-1 cells. The backbone vector (p-luc in Fig. 1)
produced no signiﬁcant luciferase signal above
autoﬂuorescent background upon treatment with
androgen, while activity of a positive control reporter
vector (MMTV-luc, containing multiple response
elements) was induced eight- to tenfold (data not
shown). Addition of a minimal tk promoter from the
herpes simplex virus (p-tk-luc) increased luciferase
signal output, producing a basal detectable level of
luciferase activity, which was not hormone-inducible,
or affected by the presence of steroid hormone
receptors (Fig. 1B). The introduction of a single copy
of a SC1.2 ARE sequence (p-tk-luc-ARE) conferred
hormone inducibility to this minimal promoter,
resulting in two- to threefold induction (Fig. 1B).
Other AREs were similarly tested; however, the SC1.2
ARE was selected as it showed the greatest degree of
hormone induction and speciﬁcity for AR, since it was
not greatly activated by other transfected or endogen-
ous steroid receptors in various cell lines (Supple-
mentary Figures 1 and 2, which can be viewed online at
http://erc.endocrinology-journals.org/supplemental/).
Next, MAR were added upstream and downstream of
the reporter cassette to generate the insulated pAR-
E.MAR vector (Fig. 1A). This was transfected into
LNCaP/TR2 cells (stably expressing the tetracycline
repressor protein; Gamble et al. 2007). Clones were
tested for androgen-inducible luciferase activity and
for cross-reactivity or activation by other steroid
hormones and their receptors. The clone selected,
named LNCaP/Luc, demonstrated strong androgen-
dependent induction of luciferase activity. The
synthetic androgen MB was the most potent activator
giving 14-fold induction of luciferase activity. The
testicular-derived androgens testosterone and DHT
gave eight- and tenfold induction of luciferase
respectively, at their physiologically relevant levels
of 1–10 nM (Fig. 1C). Since circulating adrenal
androgens are contributory but variable agonists of
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testosterone and DHT, the adrenal androgens were
weak inducers with androstenedione (A-dione) weakly
activating the reporter at 10–100 nM, concentrations
higher than the physiologically relevant normal range
(w1–5 nM). Dehydroepiandrosterone produced no
measurable signal at this range.
On treatment with MB, luciferase RNA transcripts
were detectable within 6 h (Fig. 1D) and enzymatic
activity was detectable within 16 h (data not shown).
Luciferase enzymatic activity was undetectable after
8 h of hormone starvation (data not shown). To
investigate AR occupancy of the SC1.2 ARE,
hormonally starved cells were treated with MB for
2 h and then harvested for ChIP analysis of a 200 bp
region of the constructed AR reporter, spanning the
ARE and tk promoter. As expected, AR was present on
this ARE in the presence, but in not the absence, of
hormone (Fig. 1E). Identical results were found at the
regulatory region of the endogenous androgen-respon-
sive gene, PSA.
PHB inﬂuences AR activity and cell cycle
distribution in vitro
Previously, we showed that PHB overexpression
from stably integrated tetracycline-inducible vectors
could repress androgen-dependent endogenous gene
expression and androgen-stimulated growth of LNCaP
cells in vitro (Gamble et al. 2007). Therefore, the same
doxycycline-inducible vector (pcDNA4/TO/PHB) was
used to stably transfect the LNCaP/Luc cells to
produce a new stable cell line, LNCaP/Luc/PHB-
cDNA. Additionally, a doxycycline-inducible RNAi
hairpin vector (p2TetR/PHB), based on previously
validated RNAi oligos (Gamble et al. 2004), was used
to generate an inducible PHB knockdown cell line
LNCaP/Luc/PHB-RNAi, allowing effects of manipu-
lating PHB levels to be studied within a chromatinized
system both in vitro and in vivo.
Treating LNCaP/Luc/PHB-cDNA cells with
increasing doses of doxycycline resulted in a dose-
dependent increase in PHB protein and cDNA levels
(Fig. 2A). Conversely, treating LNCaP/Luc/PHB-
RNAi cells with doxycycline resulted in a decrease
in PHB protein and cDNA levels (Fig. 2B). To assess
the effects of PHB upon AR activity, hormonally
starved LNCaP/Luc/PHB-cDNA and LNCaP/Luc/
PHB-RNAi cells were treated with increasing concen-
trations of androgen (MB), in the presence of two
different doses of doxycycline (to give submaximal
and maximal effects on PHB levels respectively),
for 24 h. Doxycycline-induced PHB overexpression
signiﬁcantly reduced the activity of the luciferase
reporter in a dose-dependent manner (Fig. 2C), while
doxycycline-induced PHB knockdown increased the
activity of the luciferase reporter in a dose-dependent
manner (Fig. 2D). The effects of modulating PHB
levels on expression of the endogenous androgen-
regulated gene, PSA, were also studied. Maximal PHB
overexpression resulted in a large reduction in PSA
expression at all MB concentrations, as measured by
real-time PCR (Fig. 2E). Conversely, PHB knockdown
resulted in increased androgen-regulated PSA
expression (Fig. 2F).
The effects of PHB manipulation on androgen-
dependent cell growth in culture were studied by FACS
analysis of doxycycline-treated cells. In full serum,
PHB overexpression (C dox) resulted in accumulation
at G1/S and a subsequent reduction in percentage of
cells in S-phase (Fig. 2G), i.e. PHB increase prevented
cell cycle entry. Hormonally starved cells showed no
signiﬁcant effects, but when treated with androgen,
PHB overexpression again reduced the percentage of
cells in S-phase. This was most evident at 10 nM MB
when cells are growing most rapidly. RNAi knock-
down of PHB did not signiﬁcantly affect the cell cycle
distribution of cells growing in full serum, presumably
since cell growth was maximal (Fig. 2H). In
hormonally starved cells, a slightly increased cell
number was seen in S-phase (4% increasing to 6%)
upon PHB knockdown. However, when hormonally
starved cells were induced to re-enter the cell cycle by
androgen treatment at 1 nM MB, the amount of cells
entering S-phase doubled with doxycycline-induced
PHB knockdown. Hence, reduction in PHB levels led
to an increase in androgen-dependent growth of
prostate cancer cells. This effect was no longer evident
when cells were treated with 10 nM MB presumably
since, as in the case of full serum, cells were already
growing at the maximum rate under these conditions.
PHB inhibits androgen-mediated growth of
prostate cancer cells in vivo
Castrated male nude mice bearing LNCaP/Luc
xenografts were used to study the effects of testoster-
one treatment on tumour growth and AR activity. Mice
were given daily injections of testosterone propionate
until tumours were conﬁrmed 2 weeks after challenge,
at which time tumours were given a relative tumour
volume (RTV) of 1. Tumours were grown to an RTV of
1.5 (w200 mm
3), and mice were then separated into
treatment groups with or without testosterone and
doxycycline. Mice given androgen supplementation
had average serum testosterone levels of 2.7 ng/ml,
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humans (3–10 ng/ml), while the vehicle control group
showed testosterone levels of !0.1 ng/ml. In testoster-
one-treated mice, tumours grew with a mean doubling
time of 15 days, until the average RTV reached 3
(w450 mm
3). However, in the vehicle control group,
tumour growth ceased upon testosterone withdrawal,
followed by statistically signiﬁcant tumour shrinkage
within 48 h (Fig. 3A), with a terminal average RTV of
0.74 after 36 days.
Androgen-induced luciferase activity within these
tumours was analysed by light emission from live
animals, imaged after i.p. injection of D-luciferin.
Tumours in testosterone-treated mice showed average
light emission of 420 photons/s per mm
3 of tumour,
whereas the tumours from vehicle-treated mice showed
a gradual drop in light emissions with a ﬁnal activity
ranging from undetectable to 200 photons/s per mm
3
(Fig. 3B and C). Histological examination and cell
proliferation counts were obtained from these two
Figure 2 Analysis of stable cell lines with altered PHB levels. (A and B) Western blot analysis of PHB levels in PHB-overexpressing
(A) and PHB-knockdown (B) cells treated with increasing doses of doxycycline for 24 h. Relative PHB cDNA values from RT-qPCR,
normalized to GAPDH, are included. (C and D) Luciferase activity from LNCaP/Luc/PHB-cDNA (C) and LNCaP/Luc/PHB-RNAi
(D) cells treated with MB (0–10 nM) and increasing doxycycline levels. (E and F) Taqman RT-PCR analysis of PSA levels from
starved LNCaP/Luc/PHB-cDNA (E) and LNCaP/Luc/PHB-RNAi (F) cells treated with increasing concentrations of MB with or without
doxycycline at 1 or 0.001 mM respectively. MeanGS.E.M. from three experiments is shown. (G and H) S-phase distributions of
LNCaP/Luc/PHB-cDNA (G) and LNCaP/Luc/PHB-RNAi (H) cells determined by FACS analysis. Cells were grown either in medium
with full serum or starvation medium GMB as indicated. **P!0.01, *P!0.05 (t-test analysis).
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effects on cellular proliferation, with tumours showing
rapid reduction in cells staining positive for the
proliferation marker Ki67 and the mitosis marker
phospho-histone H3 (Fig. 3D), demonstrating the
testosterone requirement of the LNCaP/Luc tumours.
Next, the same parameters were investigated in mice
bearing LNCaP/Luc/PHB-cDNA tumours. Serum dox-
ycycline measurements from mice indicated that
optimal serum concentrations for overexpression and
knockdown respectively were obtained by adding
200 mg/ml in drinking water for LNCaP/Luc/PHB-cDNA
xenografts and 20 mg/ml for LNCaP/Luc/PHB-RNAi
xenografts (data not shown). In testosterone-treated
mice, doxycycline treatment resulted in a statistically
signiﬁcant reduction in RTV as compared with
untreated controls, indicating that PHB overexpression
repressed androgen-mediated growth in vivo (Fig. 4A).
In the absence of testosterone, doxycycline-treated
mice showed no tumour growth, but interestingly did
not exhibit tumour shrinkage as was seen for the no
doxycycline control (Fig. 4C).
Mice bearing LNCaP/Luc/PHB-RNAi tumours, plus
testosterone, which were given doxycycline, showed a
statistically signiﬁcant increase in RTV as compared
with no doxycycline controls (Fig. 4B), indicating that
reduction in PHB levels promoted androgen-dependent
tumour growth in vivo. Without testosterone, tumours
Figure 3 Effect of testosterone withdrawal on growth of LNCaP/Luc tumour xenografts in nude mice. (A) Relative tumour volume
(RTV) of LNCaP/Luc tumours over 36 days. Each point represents the meanGS.E.M. of six to eight observations. Treatment groups
assigned on day 20. **P!0.01, *P!0.05 (Mann–Whitney analysis). (B) Light emission from LNCaP/Luc tumours normalized to
tumour volume (mm
3) at day 36. (C) Bioluminescent imaging of luciferase activity in testosterone-treated and vehicle-treated mice
harbouring LNCaP/Luc tumours at day 36, following injection with D-luciferin. (D) Immunohistochemical staining of Ki67 (upper
panel) and phospho-Histone H3 (lower panel) from sections of LNCaP/Luc tumour xenografts from mice treated with testosterone or
vehicle. Scale bar, 25 mm. Counting results from ﬁve separate tumours is shown on the right.
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increase in growth, but tumour RTVs dropped
gradually thereafter, although signiﬁcantly greater
than in the no doxycycline control animals (Fig. 4D).
Hence, a reduction in PHB levels was only partially
able to mimic androgen treatment in promoting cell
growth.
PHB represses AR activity in vivo
Light emission measurements from mice carrying
LNCaP/Luc/PHB-cDNA tumours indicated that PHB
overexpression also resulted in a signiﬁcant reduction
in androgen-mediated luciferase activity within these
tumours (Fig. 4E), with 60% less light emission. PHB
overexpression had no signiﬁcant effect in the absence
of testosterone. Conversely, reduction in PHB by
RNAi resulted in a 30% increase in androgen-mediated
luciferase activity within the tumours in the testoster-
one-treated group (Fig. 4F). Interestingly, PHB knock-
down also increased the activity of the AR in the
absence of hormone for up to 24–48 h after doxycy-
cline treatment; however, this was not maintained in
the absence of testosterone.
PHB affects cell proliferation in LNCaP/Luc
tumours
The doxycycline induction of PHB overexpression and
knockdown could clearly be seen within the tumours
by immunohistochemistry (Fig. 5A). Cell proliferation
counts were obtained from these two cell lines.
Testosterone withdrawal produced signiﬁcant effects
on cellular proliferation in both cell lines, with a rapid
reduction in cells staining positive for the proliferation
marker phospho-histone H3 (Fig. 5B and C). PHB
overexpression inhibited the testosterone-induced
cellular proliferation, as indicated by reduction in
histone H3 staining (Fig. 5B). However, PHB knock-
down resulted in a higher level of cellular proliferation
in the tumours, in the presence and absence of
testosterone (Fig. 5C).
Figure 4 Effects of manipulating PHB levels on tumour growth and AR activity in vivo. (A–D) Relative tumour volumes of LNCaP/Luc
xenograftswith increased(A and C) or decreased(B and D) PHB levelsin castratednude malemice treatedwith (A and B) or without
(C and D) testosterone. Each point represents meanGS.E.M. of six to eight tumours. **P!0.01, *P!0.05 (Mann–Whitney analysis).
(E and F) Bioluminescent imaging results from LNCaP/Luc/PHB-cDNA (E) and LNCaP/Luc/PHB-RNAi (F) tumours at day 36.
**P!0.01, *P!0.05 (t-test).
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We set out to study AR activity within a prostate
tumour xenograft model and to examine the role of a
potential corepressor protein, PHB, in modulating this
activity in a real time in vivo setting. To this end, a
doxycycline-inducible system for manipulating PHB
protein levels was generated in LNCaP cells
expressing an androgen-responsive reporter. LNCaP
cells were used as they exhibit androgen-regulated
growth and gene expression, and form xenografts in
nude mice. In humans, prostate cancer is initially
androgen dependent, but progresses to a hormone-
refractory or androgen-independent stage. The AR
remains active within the majority of these hormone-
refractory tumours and is required for prostate cell
growth, differentiation and gene expression. The
mechanisms of AR activation within such tumours
are poorly understood. AR mutations and/or ampliﬁ-
cation are frequently found in advanced tumours, and
it has been postulated that decreases in corepressor
Figure 5 Immunohistochemistry analysis of formalin-ﬁxed tumour sections. (A) PHB staining of LNCaP/Luc/PHB-cDNA
(upper panel) and LNCaP/Luc/PHB-RNAi (lower panel) from miceGdoxycycline. (B and C) Phospho-histone H3 staining
of LNCaP/Luc/PHB-cDNA (B) and LNCaP/Luc/PHB-RNAi (C) tumours from mice treatedGtestosterone and Gdoxycycline.
Phospho-histone H3-positive cell counts from ﬁve separate tumours are shown on the right. Scale bar, 25 mm.
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be potential activation pathways for the progression
of tumours to this androgen-independent stage (Isaacs
& Isaacs 2004).
PHB is a cell cycle-regulatory protein, involved
in repressing E2F-mediated gene expression, and
has been reported to repress the AR in vitro.
Overexpression of PHB in LNCaP cells inhibited
androgen-mediated cell cycle entry, cell growth and
gene expression, both in cell culture and in tumour
xenografts. However, some subtle differences were
seen in the effects of PHB in tumour xenografts. For
example, hormone starvation of LNCaP cells in
culture leads to cell cycle arrest in G0/G1, whereas
in xenografts, androgen withdrawal leads to rapid
tumour shrinkage and involution with signiﬁcant
apoptosis and/or necrosis. Indeed, a signiﬁcant
number of cells stained positive with the TUNEL
assay in these androgen-deprived tumours (Supple-
mentary data). Upon doxycycline-induced PHB over-
expression, tumour growth was inhibited even in the
presence of androgen. However, in the absence of
androgen, tumours with PHB overexpression showed
an apparent inhibition of tumour involution and
apoptosis, suggesting that PHB overexpression leads
to cell cycle arrest regardless of hormone effects, and
may consequently have a protective role against
apoptosis caused by hormonal starvation stress.
Similar protective effects have been shown for PHB
when LNCaP cells were deprived of growth factors
(Vander Heiden et al. 2002) or treated with cytotoxic
agents such as camptothecin (Fusaro et al. 2002,
Rastogi et al. 2006).
Reduction of PHB levels in LNCaP/Luc cells
increased androgen-stimulated entry into S-phase,
AR activation as measured by the luciferase assay
and increased growth. In vivo, reduction in PHB levels
resulted in an initial increase in tumour size, regardless
of androgen treatment. However, this increase in
tumour size was only maintained in the presence of
androgen. Some tumour shrinkage or involution was
seen, but no changes in apoptotic staining were
apparent (Supplementary Figure 3, which can be
viewed online at http://erc.endocrinology-journals.
org/supplemental/). These data suggest that PHB has
a potent effect in the cell, not only repressing AR
signalling but also repressing genes involved in
apoptosis and inhibiting cell cycle entry. Additionally,
the reduction in PHB protein may be sufﬁcient to
activate cell cycle and growth pathways within the cell,
avoiding or circumventing hormone starvation-
induced apoptosis.
PHB has a role in recruiting HDACs and chromatin
remodelling complexes to DNA, causing chromatin
condensation and presumably inhibiting the DNA
binding of transcription factors such as AR. Removal
of PHB via RNAi may result in decreased chromatin
condensation, making DNA more accessible for
transcription factor binding. The roles of PHB and
the AR may also overlap in their control of cell cycle
entry. The AR may play a part in DNA replication
initiation and licensing in certain cell types (Litvinov
et al. 2006), and PHB inhibits key proteins in the G1–S
transition, namely pRb and E2F (Wang et al. 1999a,b,
Balk & Knudsen 2008). It is likely that indirect
interactions or competition between AR and PHB
would arise at this G1/S boundary. Direct interaction
between AR and PHB remains elusive (Gamble et al.
2004), but recent evidence for a more direct interaction
between PHB and steroid receptors exists. PHB
associates with oestrogen-regulated promoters directly
in the absence of hormone, supporting its role as a
transcriptional corepressor (He et al. 2008), and may
physically interfere with transcription factor binding to
the response element.
From this study, PHB overexpression inhibits cell
growth, but may also protect against hormonal
starvation during anti-androgen therapy. Conversely,
a reduction in PHB levels may increase the ability of
the AR to promote cell growth and gene expression,
but could cause inappropriate cell cycle entry and
mitochondrial dysfunction. PHB is an upregulated
marker for distinguishing benign hyperplasia from
prostate cancer (Ummanni et al. 2008), but any
extensive studies on the levels of PHB protein within
prostate cancers and its effects on disease progression
are currently lacking. However, recent studies in breast
cancer indicate that the simple protein level measure-
ment was insufﬁcient, as high PHB levels masked
underlying inactivating mutations in the Rb and E2F-
binding regions of PHB (Sato et al. 1992, 1993). PHB
has been shown to be downregulated in gliomas
(Chumbalkar et al. 2005). Loss of the PHB repressor
protein may impact on the repressive effectiveness of
hormone antagonists such as the partial anti-oestrogen
tamoxifen (Wang et al. 2004) and androgen antagon-
ists (Dai et al.2 0 0 8 ), indicating that PHB may have
different tumour supporting roles at different times in
the development of hormone-dependent cancer.
Additionally, the growth-stimulating properties of
knocking down PHB in the absence of testosterone,
as seen in this study, may be due to increased activity
of AR in a low testosterone environment or indeed a
lack of repressive activity in the presence of adrenal
androgens, some of which e.g. androstenedione have
Endocrine-Related Cancer (2009) 16 1157–1169
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et al. 2004). Certainly, the current data suggest further
studies will be needed before pharmacologically
increasing corepressor protein levels, or activity
could be used as a therapeutic strategy for hormone-
dependent cancers. However, in support of this
concept, recently, a potential mechanism for in vivo
reduction in PHB levels has been suggested by Liu
et al. They reported that PHB is a potential target of the
microRNA-27a, which is upregulated in gastric
adenocarcinoma and may act as an oncogene by
reducing PHB levels (Liu et al. 2009).
Finally, there are many potential corepressors and
coactivators of AR within prostate cells, any of which
either alone or in combination may have powerful
effects upon AR signalling and hence tumour pro-
gression. We have generated a model in which the
effects of these cofactors upon AR signalling can be
studied within prostate tumour xenografts simul-
taneously with tumour growth. As proof of principle,
modulating just one of these potential corepressors
resulted in profound changes to androgen activity and
tumour growth. The generated LNCaP/Luc model has
potential as a new tool to evaluate disease progression,
the role of AR and PHB in this process, and to test new
therapies for prostate cancer treatment.
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